Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Achillion Pharmaceuticals (ACHN)

Achillion Pharmaceuticals (ACHN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 876,694
  • Shares Outstanding, K 140,047
  • Annual Sales, $ 0 K
  • Annual Income, $ -70,270 K
  • 60-Month Beta 1.62
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +832,600.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.11 +2.45%
on 11/21/19
6.39 -2.03%
on 11/15/19
-0.07 (-1.11%)
since 11/13/19
3-Month
3.48 +79.89%
on 10/15/19
6.46 -3.10%
on 11/04/19
+2.33 (+59.29%)
since 09/13/19
52-Week
1.29 +385.27%
on 12/20/18
6.46 -3.10%
on 11/04/19
+3.19 (+103.91%)
since 12/13/18

Most Recent Stories

More News
Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting

- 2.4 g/dL mean increase in hemoglobin at 24 weeks -

ACHN : 6.26 (+0.81%)
Why Is Achillion (ACHN) Down 2.8% Since Last Earnings Report?

Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ACHN : 6.26 (+0.81%)
Rigrodsky & Long, P.A. Files Class Action Suit Against Achillion Pharmaceuticals, Inc.

Rigrodsky & Long, P.A.:

ACHN : 6.26 (+0.81%)
ALXN : 110.42 (-1.82%)
5 Stocks That Pushed Russell 2000 ETF Higher

Inside the best performing stocks of the Russell 2000 ETF.

APPS : 7.34 (-3.67%)
IWM : 163.33 (-0.38%)
EVER : 33.16 (-4.79%)
CFMS : 1.54 (unch)
ACHN : 6.26 (+0.81%)
KOD : 63.45 (+0.89%)
Moore Kuehn, PLLC Encourages Investors of SRC Energy, Inc. (SRCI), Achillion Pharmaceuticals, Inc. (ACHN), and Arotech Corporation (ARTX) to Contact Firm

Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating potential claims involving the directors and officers regarding possible breaches of fiduciary...

SRCI : 3.77 (+1.34%)
ACHN : 6.26 (+0.81%)
ARTX : 2.99 (unch)
Achillion's (ACHN) Danicopan Gets EMA's PRIME Tag for PNH

Achillion's (ACHN) lead pipeline candidate danicopan receives PRIME status from the EMA as a treatment option for PNH in patients, who are not adequately responding to a C5 inhibitor.

ANIK : 53.15 (-0.65%)
ACHN : 6.26 (+0.81%)
ALXN : 110.42 (-1.82%)
NCNA : 7.25 (-8.11%)
European Medicines Agency Grants PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Not Adequately Responding to a C5 Inhibitor

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced...

ACHN : 6.26 (+0.81%)
Alexion (ALXN) Up 10 % YTD on Soliris & Ultomiris Strength

Alexion's (ALXN) stock rises 10% in the year so far as Soliris maintains momentum and Ultomiris gains further traction.

AMGN : 236.74 (+0.32%)
ACHN : 6.26 (+0.81%)
ALXN : 110.42 (-1.82%)
MITO : 11.46 (-3.78%)
Achillion Announces Clearance of Investigational New Drug Application for ACH-5228

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced...

ACHN : 6.26 (+0.81%)
Pharma Sector Tops in October: Best ETFs & Stocks

Pharma sector wins in October, making these ETFs and stocks winners.

PPH : 63.64 (-0.29%)
XPH : 41.89 (-0.19%)
PJP : 64.42 (-0.45%)
ALXN : 110.42 (-1.82%)
BIIB : 296.83 (+1.01%)
ACHN : 6.26 (+0.81%)
DERM : 12.70 (-1.32%)
GLYC : 5.96 (-3.25%)
RIGL : 2.23 (-1.33%)
IRWD : 12.79 (+1.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ACHN with:

Business Summary

ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused...

See More

Key Turning Points

2nd Resistance Point 6.31
1st Resistance Point 6.28
Last Price 6.26
1st Support Level 6.23
2nd Support Level 6.20

See More

52-Week High 6.46
Last Price 6.26
Fibonacci 61.8% 4.49
Fibonacci 50% 3.88
Fibonacci 38.2% 3.26
52-Week Low 1.29

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar